Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG-IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir-based triple therapy for patients with prior telaprevir treatment failure. This multicentre, observational cohort consisted of 345 consecutive Japanese patients infected with HCV genotype 1b, including 20 who had experienced telaprevir-based triple therapy. Amino acid substitutions in the NS3/4A region were identified by direct sequencing at the time of relapse or breakthrough in treatment with telaprevir and at the initiation of treatment with simeprevir. Patients were stratified according to prior response to PEG-IFNα and ribavirin. Of the 20 patients with telaprevir treatment failure, 10 (50.0

作者：E, Ogawa；N, Furusyo；K, Dohmen；E, Kajiwara；A, Kawano；H, Nomura；K, Takahashi；T, Satoh；K, Azuma；M, Nakamuta；T, Koyanagi；K, Kotoh；S, Shimoda；J, Hayashi

来源：Journal of viral hepatitis 2015 年 22卷 12期